Results 91 to 100 of about 2,297 (166)

A Review of Pityriasis Rosea in Relation to SARS-CoV-2/COVID-19 Infection and Vaccination. [PDF]

Cureus, 2023
Wong N, Cascardo CA, Mansour M, Qian V, Potts GA.   +4 more
europepmc   +1 more source

Atypical Rash as a Presentation of Pityriasis Rosea in a 23-Month-Old. [PDF]

Cureus
Tilak K, Ray E, Joseph M.
europepmc   +1 more source

Pityriasis rosea during COVID-19 and its pathogenesis. [PDF]

JAAD Int, 2022
Drago F, Ciccarese G.
europepmc   +1 more source

Pityriasis rosea-like drug eruption secondary to deucravacitinib. [PDF]

JAAD Case Rep
Punchihewa N, Lee S, Tan CG, Foley P.
europepmc   +1 more source

Pityriasis Rosea and Immunosuppressive Drugs [Letter]. [PDF]

Clin Cosmet Investig Dermatol
Drago F, Fidanzi C, Ciccarese G.
europepmc   +1 more source

Herald Patch as the Only Evidence of Pityriasis Rosea: Clinical, Laboratory and Pathogenetic Features. [PDF]

Viruses
Drago F, Herzum A, Varesano S, Serviddio G, Broccolo F, Ciccarese G.   +5 more
europepmc   +1 more source

Inverse Pityriasis Rosea [PDF]

Indian Pediatrics, 2019
Nadia Ghariani, Fetoui, Lobna, Boussofara   +1 more
openaire   +2 more sources

Pityriasis rosea and pityriasis rosea-like eruption: The distinction is relevant for diagnostic and prognostic reasons. [PDF]

J Family Community Med
Ciccarese G, Serviddio G, Drago F.
europepmc   +1 more source

Pityriasis rosea and pityriasis rosea-like eruption after anti-SARS-CoV-2 vaccination: a report of five cases and review of the literature. [PDF]

Dermatol Reports, 2023
Veraldi S, Boneschi V, Cusini M, Maronese CA.   +3 more
europepmc   +1 more source

A retrospective analysis of medications associated with pityriasis rosea reported in the FDA adverse events reporting system. [PDF]

Arch Dermatol Res
Mashoudy KD, Ye-Tay J, Nouri K.
europepmc   +1 more source